Your browser doesn't support javascript.
loading
Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States
Asieh Golozar; Lana YH Lai; Anthony Sena; David Vizcaya; Lisa M Schilling; Vojtech Huser; Fredrik Nyberg; Scott L Duvall; Daniel R Morales; Thamir M Alshammari; Hamed Abedtash; Waheed-Ul-Rahman Ahmed; Osaid Alser; Heba Alghoul; Ying Zhang; Mengchun Gong; Yin Guan; Carlos Areia; Jitendra Jonnagaddala; Karishma Shah; Jennifer C Lane; Albert Prats-Uribe; Jose D Posada; Nigam H Shah; Vignesh Subbian; Lin Zhang; Maria Tereza Fernandes Abrahao; Peter R Rijnbeek; Seng Chan You; Paula Casajust; Elena Roel; Martina Recalde; Sergio Fernandez-Bertolin; Alan Andryc; Jason A Thomas; Adam B Wilcox; Stephen Fortin; Clair Blacketer; Frank DeFalco; Karthik Natarajan; Thomas Falconer; Matthew Spotnitz; Anna Ostropolets; George Hripcsak; Marc Suchard; Kristine E Lynch; Michael E Matheny; Andrew Williams; Christian Reich; Talita Duarte-Salles; Kristin Kostka; Patrick B Ryan; DANIEL PRIETO-ALHAMBRA.
Afiliación
  • Asieh Golozar; Regeneron Pharmaceutical, NY USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, MD USA
  • Lana YH Lai; Division of Cancer Sciences, School of Medical Sciences, University of Manchester, UK
  • Anthony Sena; Janssen R&D, Titusville NJ, USA; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • David Vizcaya; Bayer Pharmaceuticals, Sant Joan Despi, Spain
  • Lisa M Schilling; Data Science to Patient Value Program, University of Colorado Anschutz Medical Campus
  • Vojtech Huser; National Library of Medicine, National Institutes of Health, Bethesda, MD, USA
  • Fredrik Nyberg; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  • Scott L Duvall; VINCI, VA Salt Lake City Health Care System, Salt Lake City, VA, & Division of Epidemiology, University of Utah, Salt Lake City, UT
  • Daniel R Morales; Division of Population Health and Genomics, University of Dundee, UK
  • Thamir M Alshammari; Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia
  • Hamed Abedtash; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
  • Waheed-Ul-Rahman Ahmed; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK College of Medicine and Health, University of E
  • Osaid Alser; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • Heba Alghoul; Faculty of Medicine, Islamic University of Gaza, Palestine
  • Ying Zhang; DHC Technologies Co. Ltd, Beijing, China
  • Mengchun Gong; DHC Technologies Co. Ltd, Beijing, China
  • Yin Guan; DHC Technologies Co. Ltd, Beijing, China
  • Carlos Areia; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Jitendra Jonnagaddala; School of Public Health and Community Medicine, UNSW Sydney, Australia
  • Karishma Shah; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Jennifer C Lane; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Albert Prats-Uribe; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Jose D Posada; Stanford University School of Medicine, Stanford, California, USA
  • Nigam H Shah; Stanford University School of Medicine, Stanford, California, USA
  • Vignesh Subbian; College of Engineering, The University of Arizona, Tucson, Arizona, USA
  • Lin Zhang; School of Population Medicine and Public Health, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China; Melbourne School of Popul
  • Maria Tereza Fernandes Abrahao; Faculty Medicine University of Sao Paulo, Sao Paulo, Brazil
  • Peter R Rijnbeek; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Seng Chan You; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea
  • Paula Casajust; Real-World Evidence, Trial Form Support, Barcelona, Spain
  • Elena Roel; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Martina Recalde; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; Universitat Autonoma de Barcelon
  • Sergio Fernandez-Bertolin; Fundacio Institut Universitari per a la recerca a l'Atencil Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Alan Andryc; Janssen R&D, Titusville NJ, USA
  • Jason A Thomas; Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA
  • Adam B Wilcox; Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA UW; Medicine, Seattle, WA, USA
  • Stephen Fortin; Observational Health Data Analytics, Janssen Research and Development, Raritan, NJ, USA
  • Clair Blacketer; Janssen R&D, Titusville NJ, USA; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Frank DeFalco; Janssen R&D, Titusville NJ, USA
  • Karthik Natarajan; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA; New York-Presbyterian Hospital, 622 W 168 St, PH20 New
  • Thomas Falconer; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • Matthew Spotnitz; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • Anna Ostropolets; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • George Hripcsak; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA; New York-Presbyterian Hospital, 622 W 168 St, PH20 New
  • Marc Suchard; Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, USA
  • Kristine E Lynch; VINCI, VA Salt Lake City Health Care System, Salt Lake City, VA, & Division of Epidemiology, University of Utah, Salt Lake City, UT
  • Michael E Matheny; VINCI, Tennessee Valley Healthcare System VA, Nashville, TN & Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN
  • Andrew Williams; Tufts Institute for Clinical Research and Health Policy Studies, US
  • Christian Reich; Real World Solutions, IQVIA, Cambridge, MA, USA
  • Talita Duarte-Salles; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Kristin Kostka; Real World Solutions, IQVIA, Cambridge, MA, USA
  • Patrick B Ryan; Janssen R&D, Titusville NJ, USA; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • DANIEL PRIETO-ALHAMBRA; University of Oxford
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20218875
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
Early identification of symptoms and comorbidities most predictive of COVID-19 is critical to identify infection, guide policies to effectively contain the pandemic, and improve health systems response. Here, we characterised socio-demographics and comorbidity in 3,316,107persons tested and 219,072 persons tested positive for SARS-CoV-2 since January 2020, and their key health outcomes in the month following the first positive test. Routine care data from primary care electronic health records (EHR) from Spain, hospital EHR from the United States (US), and claims data from South Korea and the US were used. The majority of study participants were women aged 18-65 years old. Positive/tested ratio varied greatly geographically (2.2100 to 31.2100) and over time (from 50100 in February-April to 6.8100 in May-June). Fever, cough and dyspnoea were the most common symptoms at presentation. Between 4%-38% required admission and 1-10.5% died within a month from their first positive test. Observed disparity in testing practices led to variable baseline characteristics and outcomes, both nationally (US) and internationally. Our findings highlight the importance of large scale characterization of COVID-19 international cohorts to inform planning and resource allocation including testing as countries face a second wave.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint